Remove Resources Cell-lines
article thumbnail

Understanding Large Molecule Drug Development: From Biologics to Market

Impact Pharmaceutical Services

Cell Line Development Demand for biologics has impacted the cell line development (CLD) market, expected to reach $1.7 This improves productivity, scalability, and stability of cell lines, while reliable data sharing propels timelines and goals. billion by 2028.

article thumbnail

Novel delivery approach demonstrates efficacy of immunotherapy

European Pharmaceutical Review

Leptomeningeal disease is a cancer complication that occurs when cancer cells from primary tumours migrate into the cerebrospinal fluid (CSF) and leptomeninges, the outer lining of the brain and spinal cord. These cells can quickly spread throughout the CSF and cause a variety of neurological symptoms.

82
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Collaboration to support quality production of biologics

European Pharmaceutical Review

#atccnews [link] pic.twitter.com/LF38xxYvWM — ATCC (@officialatcc) February 23, 2023 The solutions the organisations will launch together include: Genomic DNA from top cell lines used in bioproduction Measurement of cellular DNA left over following purification is required by regulatory authorities to ensure product safety.

77
article thumbnail

Reaction Biology to acquire Vyant Bio subsidiary’s operations in US

Pharmaceutical Technology

Reaction will also obtain lab facilities, equipment, staff, cell lines and expertise in toxicology, pharmacology, pathology and bio analytics from vivoPharm. The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise.

52
article thumbnail

NICE says yes to BeiGene’s Brukinsa after Scottish nay

pharmaphorum

That approval also included first-line use of the drug for eligible patients unsuitable for chemo-immunotherapy, typically carried out with bendamustine plus rituximab or dexamethasone plus rituximab and cyclophosphamide. Second indication coming.

article thumbnail

MorphoSys slims down, narrowing its focus to cancer

pharmaphorum

MorphoSys’ chief executive Jean-Paul Kress said the deal will allow the biotech to “focus our resources on driving our late- and mid-stage oncology pipeline forward.”

87
article thumbnail

Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancer

pharmaphorum

UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement” with the company. The post Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancer appeared first on.

65